The Frequent Traveler Benefit People Want More Than Perks


Kemper (KMPR) reported $1.22 billion in revenue for the quarter ended September 2023, representing a year-over-year decline of 12.8%. EPS of -$0.44 for the same period compares to -$0.48 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.19 billion, representing a surprise of +2.86%. The company delivered an EPS surprise of +10.20%, with the consensus EPS estimate being -$0.49.

While investors closely watch year-over-year changes in headline numbers — revenue and earnings — and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company’s underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock’s price performance.

Here is how Kemper performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total Incurred Loss and LAE Ratio – Specialty Property & Casualty Insurance – Commercial Automobile Insurance: 82.2% compared to the 80.4% average estimate based on two analysts.
  • Total Incurred Loss and LAE Ratio – Specialty Property & Casualty Insurance – Personal Automobile Insurance: 91.1% versus the two-analyst average estimate of 87.3%.
  • Revenues- Life and Health Insurance- Earned premiums: $102.10 million versus the three-analyst average estimate of $122.67 million. The reported number represents a year-over-year change of -35.5%.
  • Revenues- Earned premiums: $1.12 billion versus the three-analyst average estimate of $1.13 billion. The reported number represents a year-over-year change of -14.5%.
  • Revenues- Net investment income: $81.60 million versus the three-analyst average estimate of $107.73 million. The reported number represents a year-over-year change of -16.6%.
  • Revenues- Specialty Property & Casualty Insurance- Earned Premiums- Personal Automobile: $724 million versus $751 million estimated by two analysts on average.
  • Revenues- Life and Health Insurance- Net investment income: $49.40 million versus $53.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.1% change.
  • Revenues- Life and Health Insurance- Total: $151.60 million versus $157.96 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -28.1% change.
  • Revenues- Life and Health Insurance- Earned premiums- Accident and Health: $5.80 million compared to the $5.30 million average estimate based on two analysts. The reported number represents a change of -87.4% year over year.
  • Revenues- Life and Health Insurance- Earned premiums- Life: $84.90 million versus the two-analyst average estimate of $87.81 million. The reported number represents a year-over-year change of -15.4%.
  • Revenues- Life and Health Insurance- Earned premiums- Property: $11.40 million versus the two-analyst average estimate of $11.05 million. The reported number represents a year-over-year change of -4.2%.
  • Revenues- Specialty Property & Casualty Insurance- Total: $935.20 million versus $961.91 million estimated by two analysts on average.

View all Key Company Metrics for Kemper here>>>

Shares of Kemper have returned -1.8% over the past month versus the Zacks S&P 500 composite’s -3.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.

It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Kemper Corporation (KMPR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



Image and article originally from www.nasdaq.com. Read the original article here.

By Zacks